Table 2.
Targeted therapy | First-line RR | Second-line RR |
---|---|---|
Sunitinib | 31 % (69/226) | 18 % (22/125) |
Sorafenib | 14 % (19/139) | 6 % (11/171) |
Bevacizumab | 10 % (6/59) | 0 % (0/20) |
Axitinib | N/A | 36 % (4/11) |
Pazopanib | N/A | 0 % (0/2) |
Patient numbers are small and comparisons should not be made. Denominators are based on the availability of response information for each patient